Abstract
Despite the introduction of more than 15 third generation antiepileptic drugs to the market from 1990 to the moment, about one third of the epileptic patients still suffer from refractory to intractable epilepsy. Several hypotheses seek to explain the failure of drug treatments to control epilepsy symptoms in such patients. The most studied one proposes that drug resistance might be related with regional overactivity of efflux transporters from the ATP-Binding Cassette (ABC) superfamily at the blood-brain barrier and/or the epileptic foci in the brain. Different strategies have been conceived to address the transporter hypothesis, among them inhibiting or down-regulating the efflux transporters or bypassing them through a diversity of artifices. Here, we review scientific evidence supporting the transporter hypothesis along with its limitations, as well as computer-assisted early recognition of ABC transporter substrates as an interesting strategy to develop novel antiepileptic drugs capable of treating refractory epilepsy linked to ABC transporters overactivity.
Keywords: ABC transporters, ABCB1, ABCG2, antiepileptic drugs, breast Cancer resistance Protein, drug discovery, P-glycoprotein, refractory epilepsy, transporter hypothesis.
Mini-Reviews in Medicinal Chemistry
Title:Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy
Volume: 17 Issue: 3
Author(s): Manuel Couyoupetrou, Melisa E. Gantner, Mauricio E. Di Ianni, Pablo H. Palestro, Andrea V. Enrique, Luciana Gavernet, Maria E. Ruiz, Guido Pesce, Luis E. Bruno-Blanch and Alan Talevi
Affiliation:
Keywords: ABC transporters, ABCB1, ABCG2, antiepileptic drugs, breast Cancer resistance Protein, drug discovery, P-glycoprotein, refractory epilepsy, transporter hypothesis.
Abstract: Despite the introduction of more than 15 third generation antiepileptic drugs to the market from 1990 to the moment, about one third of the epileptic patients still suffer from refractory to intractable epilepsy. Several hypotheses seek to explain the failure of drug treatments to control epilepsy symptoms in such patients. The most studied one proposes that drug resistance might be related with regional overactivity of efflux transporters from the ATP-Binding Cassette (ABC) superfamily at the blood-brain barrier and/or the epileptic foci in the brain. Different strategies have been conceived to address the transporter hypothesis, among them inhibiting or down-regulating the efflux transporters or bypassing them through a diversity of artifices. Here, we review scientific evidence supporting the transporter hypothesis along with its limitations, as well as computer-assisted early recognition of ABC transporter substrates as an interesting strategy to develop novel antiepileptic drugs capable of treating refractory epilepsy linked to ABC transporters overactivity.
Export Options
About this article
Cite this article as:
Couyoupetrou Manuel, Gantner E. Melisa, Di Ianni E. Mauricio, Palestro H. Pablo, Enrique V. Andrea, Gavernet Luciana, Ruiz E. Maria, Pesce Guido, Bruno-Blanch E. Luis and Talevi Alan, Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy, Mini-Reviews in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1389557516666161013103408
DOI https://dx.doi.org/10.2174/1389557516666161013103408 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics Serotonergic 5-HT2C Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs
Current Topics in Medicinal Chemistry The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Current Drug Metabolism Human Disease and Drug Pharmacology, Complex as Real Life
Current Medicinal Chemistry Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Random Walks on Biomedical Networks
Current Proteomics Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Neuroimaging methods in Epilepsy of Temporal Origin
Current Medical Imaging Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics HCN Channel as Therapeutic Targets for Heart Failure and Pain
Current Topics in Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents